Top Markets
#1 Velas Velas +367.72%
#2 Gravity Gravity +48.70%
#3 Galxe Galxe +41.28%
#4 Infinity Ground Infinity Ground +30.80%
#5 Wiki Cat Wiki Cat +26.84%
#6 Audiera Audiera +26.57%
#7 Fetch.ai Fetch.ai +26.24%
#8 Derive Derive +24.86%
#9 Aria.AI Aria.AI +20.75%
#10 Babylon Babylon +18.83%
Coin of the day
Velas Velas
Settings
Language
ENGLISH
Currency
USD
Theme
MultiCell Technologies, Inc. MultiCell Technologies, Inc.

MultiCell Technologies, Inc.

MCET
Rank in Stocks #20718
MultiCell Technologies, Inc., a biopharmaceutical company, develops novel... MultiCell Technologies, Inc., a biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications. Its product portfolio comprises MCT-125, a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-465, a preclinical synthetic double-stranded RNA (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers; and MCT-485, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of various cancers. The company also develops Ideal BioStent, a bioabsorbable stent for interventional cardiology and peripheral vessel applications. MultiCell Technologies, Inc. has a license agreement with Corning Incorporated and Pfizer Inc. The company was formerly known as Exten Industries, Inc. and changed its name to MultiCell Technologies, Inc. in April 2004. MultiCell Technologies, Inc. was founded in 1962 and is headquartered in Woonsocket, Rhode Island.
Share Price
$0.00001
Market Cap
$50.01K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade MultiCell Technologies, Inc. (MCET)

Category

Healthcare
Market Capitalization
Revenue
more
Earnings
Price History
P/E Ratio
P/S Ratio
P/B Ratio
Operating Margin
EPS
Stock Splits
Dividends
Dividend Yield
Shares Outstanding
Operating Margin for MultiCell Technologies, Inc. (MCET)
Operating Margin as of March 2026 TTM: -1,465.60%
According to MultiCell Technologies, Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is -1,465.60%. At the end of 2013 the company had an Operating Margin of -2,773.89%.
Operating Margin history for MultiCell Technologies, Inc. from 2013 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) -1,465.60% 0.00%
2014 -1,465.60% -47.16%
2013 -2,773.89% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
41.30% -100.03%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
35.45% -100.02%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
24.95% -100.02%
US
UCB SA UCB SA
UCB SA
UCB.BR
25.32% -100.02%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -100.02%
AU
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.